Compare Kyndryl Holdings Inc (KD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Novo Nordisk A/S — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 63.8× Kyndryl Holdings Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Novo Nordisk A/S for 116 Days on average.
| KD | NVO | |
|---|---|---|
Market Cap | $2.59B | $165.31B |
Volume | 5,354,348 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $29.76 | $63.98 |
52-Week Low | $10.59 | $35.29 |
Typical Hold Time | 36 Days | 116 Days |
Enterprise Value | $5.41B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $11.88, up 3.76% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q4 2025 and Q1 2026 expectations. Fundamentals show improving profitability with 2025 net income of $252M (1.67% margin) and strong cash flow generation of $236M. Recent news highlights AI-focused initiatives including new innovation labs and strategic acquisitions.
Outlook remains cautious with analyst consensus at Hold (71.42%) and $14.67 price target offering 23% upside. Key risks include inconsistent earnings performance, competitive pressures in IT services, and high debt levels at 30.67% debt-to-asset ratio. The stock presents potential for recovery if AI investments translate to sustained revenue growth and margin expansion.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
